Results 111 to 120 of about 827 (180)

Impacto del programa de optimización de uso de antimicrobianos (PROA) colaborativo con el programa de optimización del diagnóstico microbiológico (PRODIM) en pacientes con infección del tracto respiratorio inferior de la Unidad de Cuidados Intensivos de adultos del Hospital General del Sur de Quito, desde abril a diciembre de 2023 [PDF]

Introducción: Las infecciones del tracto respiratorio inferior en la UCI (neumonía asociada a la ventilación mecánica (NAV) y traqueobronquitis asociada a la ventilación mecánica (TBAVM) se asocian con hospitalizaciones prolongadas, costos elevados y ...
Villacrés Villacreses, Ivonne Alexandra, Zhunio Zhunio, Daniel Gerardo   +1 more
core   +1 more source

Antimicrobial Resistance in ESKAPE Pathogens: A Retrospective Epidemiological Study at the University Hospital of Palermo, Italy [PDF]

Background: Antimicrobial resistance (AMR) is an escalating global health threat, projected to cause over 40 million deaths by 2050. ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii ...
Bono E., Bonura C., Cascio A., D'Agati G., Distefano S. A., Firenze A., Giammanco G. M., Mazzola C. V., Pipito L., Rubino R., Urso S., Zinna G.   +11 more
core   +1 more source

Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens for Mycobacterium abscessus Lung Disease

ABSTRACT Background IDSA guideline-based therapy achieves sputum culture conversion rates in 20-34% of patients with Mycobacterium abscessus (MAB) lung disease (LD).
Sanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula, Mary C Long, Brian Robbins, Pamela J McShane, Tawanda Gumbo, Shashikant Srivastava   +7 more
openaire   +2 more sources

P40 Evaluation of sulbactam/durlobactam activity against carbapenem-resistant Acinetobacter baumannii in India: an institutional experience

JAC-Antimicrobial Resistance
Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) is a WHO designated ‘critical priority’ pathogen because of its high capacity for multidrug resistance and association with mortality rates approaching 50% in severe hospital-acquired infections.
Nizam Ahmed, M, Singh, Parul, Kirti, Madhavi, Das, Bharat Chandra, Tluanpuii, Vanlal, Kumar, Subodh, Sagar, Sushma, Soni, Kapil Dev, Aggarwal, Richa, Bindra, Ashish, Goyal, Keshav, Singh, Gyanendra Pal, Sokhal, Navdeep, Farooque, Kamran, Mathur, Purva   +14 more
openaire   +1 more source

Precision Approaches to Carbapenem-Resistant Infections in the ICU: Integrating Diagnostics, Stewardship, and Novel Therapies

Diagnostics
Carbapenem-resistant Gram-negative infections have become one of the most formidable challenges in intensive care units (ICUs). Critically ill patients—often exposed to invasive procedures, prolonged hospitalization, and broad-spectrum antibiotics—are ...
Rocco Morena, Sara Palma Gullì, Francesca Serapide, Alessandro Russo   +3 more
doaj   +1 more source

Resistance to oxyimino-cephalosporins conferred by an alternative mechanism of hydrolysis by the Acinetobacter-derived cephalosporinase-33 (ADC-33), a class C β-lactamase present in carbapenem-resistant Acinetobacter baumannii (CRAb) [PDF]

Antimicrobial resistance in Acinetobacter baumannii is partly mediated by chromosomal class C beta-lactamases, the Acinetobacter-derived cephalosporinases (ADCs).
Bethel, Christopher R., Bonomo, Robert A., Caselli, Emilia, Hujer, Andrea M., Hujer, Kristine M., Jarvis, Hannah R., June, Cynthia M., Powers, Rachel A., Prati, Fabio, Rudin, Susan D., Taracila, Magdalena A., Wallar, Bradley J., Ziegler, Zoe X.   +12 more
core   +1 more source

Antibiotic resistance genotype, phenotype, and clinical outcomes in patients with Gram-negative infections at Rabin Medical Center in Israel

Microbiology Spectrum
Antibiotic resistance is a major cause of morbidity and mortality. However, a better understanding of the relationship between bacterial genetic markers, phenotypic resistance, and clinical outcomes is needed. We performed whole-genome sequencing on five
Rachelle E. Koch, Jackson Barth, Andrew E. Clark, Dhara Desai, Jiwoong Kim, Christine A. Pybus, Xiaowei Zhan, Leonard Leibovici, Dafna Yahav, David E. Greenberg   +9 more
doaj   +1 more source

Open Repository @ Binghamton Monthly Additions and Top Downloads - August 2025 [PDF]

Newly added work in the Open Repository @ Binghamton (ORB) from 8/1/2025-8/31/2025.
Holton, Caitlin
core   +1 more source

Open Repository @ Binghamton Monthly Additions and Top Downloads - June 2025 [PDF]

Newly added work in the Open Repository @ Binghamton (ORB) from 6/1/2025-6/30/2025.
Holton, Caitlin
core   +1 more source

Analyzing US FDA-Approved Infectious Disease Drugs from 2015-2023 [PDF]

Primary Author: Rizamari May Pascua Co-Authors: Tracy Pham, Dianqing Sun, PhD Presentation Title: Analyzing US FDA-Approved Infectious Disease Drugs from 2015-2023 Purpose: In 2019, there are approximately 10.2 million hospital visits for infectious and ...
Rizamari May Pascua, Tracy Pham, Dianqing Sun
core   +1 more source